BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 25958817)

  • 1. Expectant management for men with early stage prostate cancer.
    Filson CP; Marks LS; Litwin MS
    CA Cancer J Clin; 2015; 65(4):265-82. PubMed ID: 25958817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.
    Chou R; Croswell JM; Dana T; Bougatsos C; Blazina I; Fu R; Gleitsmann K; Koenig HC; Lam C; Maltz A; Rugge JB; Lin K
    Ann Intern Med; 2011 Dec; 155(11):762-71. PubMed ID: 21984740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
    Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical review: is watchful waiting a viable management option for older men with prostate cancer?
    Bailey DE; Wallace M
    Am J Mens Health; 2007 Mar; 1(1):18-28. PubMed ID: 19482780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual function with localized prostate cancer: active surveillance vs radical therapy.
    van den Bergh RC; Korfage IJ; Roobol MJ; Bangma CH; de Koning HJ; Steyerberg EW; Essink-Bot ML
    BJU Int; 2012 Oct; 110(7):1032-9. PubMed ID: 22260273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional treatments of localized prostate cancer.
    Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
    Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evidence review of active surveillance in men with localized prostate cancer.
    Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
    Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based assessment of determining predictors for quality of prostate cancer surveillance.
    Chamie K; Williams SB; Hershman DL; Wright JD; Nguyen PL; Hu JC
    Cancer; 2015 Dec; 121(23):4150-7. PubMed ID: 26307939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.
    Eifler JB; Alvarez J; Koyama T; Conwill RM; Ritch CR; Hoffman KE; Resnick MJ; Penson DF; Barocas DA;
    J Urol; 2017 Mar; 197(3 Pt 1):614-620. PubMed ID: 27984110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial.
    Bill-Axelson A; Garmo H; Holmberg L; Johansson JE; Adami HO; Steineck G; Johansson E; Rider JR
    Eur Urol; 2013 Dec; 64(6):920-8. PubMed ID: 23465517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LOW RISK PROSTATE CANCER: ACTIVE TREATMENT OR ACTIVE SURVEILLANCE?
    Tomašković I
    Acta Clin Croat; 2015 Sep; 54(3):337-44. PubMed ID: 26666105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The watchful waiting management option for older men with prostate cancer: state of the science.
    Wallace M; Bailey D; O'Rourke M; Galbraith M
    Oncol Nurs Forum; 2004 Nov; 31(6):1057-66. PubMed ID: 15547629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer.
    Anai S; Nakamura K; Chang MN; Pendleton J; Yacoub S; Rosser CJ
    J Health Care Poor Underserved; 2008 Feb; 19(1):164-70. PubMed ID: 18263992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing outcomes in genitourinary cancers across the treatment continuum.
    Fitzpatrick JM; Bellmunt J; Dreicer R; Fleshner NE; Logothetis CJ; Moul JW; Tombal B; Zlotta A
    BJU Int; 2011 Apr; 107 Suppl 2():1-12. PubMed ID: 21382149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.